Published in Allergy on October 01, 2006
A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J (2013) 1.51
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study. Clin Transl Allergy (2016) 0.79
Sensitization to timothy grass pollen allergenic molecules in children. Multidiscip Respir Med (2013) 0.76
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
Standards for practical allergen-specific immunotherapy. Allergy (2006) 2.70
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest (1998) 1.84
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy (2007) 1.75
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet (1998) 1.56
Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol (1999) 1.52
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy (2005) 1.51
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy (2000) 1.50
Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy (2001) 1.50
Allergic rhinitis in the Italian population evaluated through the national database of general practitioners. Allergy (2007) 1.48
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45
Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J (2010) 1.41
The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr) (2012) 1.41
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med (1995) 1.40
In situ hybridization analysis of ICAM-1 (CD54) mRNA on conjunctival epithelium during allergic inflammation. Clin Exp Allergy (1997) 1.40
Incidence of digestive diseases in patients with adverse reactions to foods. Ann Allergy (1988) 1.40
Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy (2003) 1.35
The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy (2009) 1.34
Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy (2003) 1.34
GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy (2010) 1.28
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy (2014) 1.22
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol (2001) 1.19
Imbalances of T cell subpopulations in patients with atopic diseases and effect of specific immunotherapy. J Immunol (1979) 1.19
Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. J Allergy Clin Immunol (1995) 1.19
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol (1998) 1.15
Mast cells in the airway lumen and bronchial mucosa of patients with chronic bronchitis. Am J Respir Crit Care Med (1994) 1.14
Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy (2012) 1.13
Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy (2003) 1.13
Expression of intercellular adhesion molecule-1 (ICAM-1) on thyroid epithelial cells in Hashimoto's thyroiditis but not in Graves' disease or papillary thyroid cancer. Clin Exp Immunol (1991) 1.11
Effects of sublingual immunotherapy in patients sensitised to Ambrosia. An open controlled study. Allergol Immunopathol (Madr) (2001) 1.09
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Systemic reactions from skin testing: literature review. J Investig Allergol Clin Immunol (2006) 1.06
ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy (2008) 1.05
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol (1995) 1.05
Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy (2006) 1.05
Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy (2004) 1.04
Social hackers: integration in the host chemical recognition system by a paper wasp social parasite. Naturwissenschaften (2000) 1.04
From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther (2012) 1.04
On the functional consequences of bronchial basement membrane thickening. J Appl Physiol (1985) (2001) 1.04
GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy (2009) 1.03
Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol (1995) 1.02
Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy (2007) 1.01
The classification of allergic rhinitis and its cytological correlate. Allergy (2011) 1.00
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol (2004) 1.00
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy (2009) 0.99
Sleep disturbances and asthma control: a real life study. Asian Pac J Allergy Immunol (2009) 0.98
Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy (2005) 0.98
Cell therapy: achievements and perspectives. Haematologica (1999) 0.98
Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98
Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy (2008) 0.97
Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97
Variation in cuticular hydrocarbon signatures, hormonal correlates and establishment of reproductive dominance in a polistine wasp. J Insect Physiol (2004) 0.96
Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy (2005) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
Effects of pulmonary rehabilitation on lung function in chronic obstructive pulmonary disease: the FIRST study. Eur J Phys Rehabil Med (2014) 0.95
The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA(2)LEN review. Allergy (2008) 0.95
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy (2011) 0.95
The nocebo effect during oral challenge in subjects with adverse drug reactions. Eur Ann Allergy Clin Immunol (2008) 0.94
Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy (2003) 0.94
Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy (2005) 0.94
Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol (2012) 0.94
The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy (2008) 0.94